ClearPoint Neuro (CLPT) Projected to Post Quarterly Earnings on Tuesday

Posted by Dante Gardener on Mar 4th, 2025

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $8.23 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $8.23 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

Shares of CLPT stock opened at $13.55 on Tuesday. The firm’s 50 day moving average price is $16.62 and its 200-day moving average price is $13.91. ClearPoint Neuro has a one year low of $5.11 and a one year high of $19.22. The firm has a market cap of $374.41 million, a P/E ratio of -19.64 and a beta of 1.03.

Analyst Ratings Changes

Several equities analysts have recently commented on CLPT shares. Lake Street Capital upped their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, January 21st. B. Riley upped their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th.

View Our Latest Analysis on ClearPoint Neuro

ClearPoint Neuro Company Profile

(Get Free Report)

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.